

12-Nov-2024

Eli Lilly and Company Limited

8 Arlington Square West  
Downshire Way  
Bracknell  
RG12 1PU  
England

Dr Olivia Smith  
Berkshire Hospital  
11 Hillberry  
Bracknell  
RG12 5EG

www.lilly.com/uk  
Tel: 0203 1620044  
Email: uk\_team\_gbmailgps@lilly.com

Dear Dr Olivia Smith,

**Company Reference Number: GB202455660052**

**Re: Mounjaro (tirzepatide) – Gender patient: Female [Name: Claudia Martins/Initials: CM, DOB: 13-Oct-2024] who experienced Diarrhea**

On **12-Oct-2024** the company received this adverse event report via our (tirzepatide) patient support programme. The patient gave us permission to follow up on this report and they provided your details as their treating doctor. I trust it is acceptable to contact you for follow-up for this case.

As you know, collection of post-marketing safety information on medicines is vital for the continuing improvement of our understanding of their use in normal clinical practice. As part of our commitment to patient safety, Lilly collects and collates information on adverse drug events. This data is transmitted to regulatory authorities such as the MHRA and is used to update prescribing information and to ensure that we are able to provide healthcare providers and patients with the most comprehensive advice available on our medicines.

We would be grateful if you would please complete **or forward to the doctor concerned** the enclosed spontaneous follow-up form. Please include product lot number information, if available.

Eli Lilly & Company UK are appreciative of any information you are able to provide. As a marketing authorisation holder, we rely on reports from HCPs and consumers regarding patient experience to continuously monitor the safety profile of our products accurately, thereby ensuring that HCPs, public, and regulators are kept informed as to the risks associated with any given product, and any actions that can mitigate them.

Lilly advises that all patients are informed if an adverse event has been reported that relates to them.

Thank you for your co-operation, we appreciate the time and trouble taken to assist us.

Yours sincerely,

**Global Patient Safety**

Encs: Pre-paid envelope

*DATA PROTECTION NOTICE: All the information and personal data you share with Lilly will be protected and kept confidential in line with Company policies and local regulations. The information you provide will be used for the purpose of drug safety surveillance and may be shared with health authorities. Full privacy notice can be found here: <https://privacynotice.lilly.com>*